Precision BioSciences has dosed the first individual with their novel gene editing approach for individuals with Duchenne mutations between exons 45 and 55

Precision BioSciences has shared that the first participant in the FUNCTION_DMD clinical trial has received their investigational gene editing treatment, PBGENE-DMD.  PBGENE-DMD delivers ARCUS nucleases via AAV9 to cut out exons 45-55 of the dystrophin gene, a therapeutic approach amenable to individuals with Duchenne with mutations in that region.

Link to press release:  https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-commences-dosing-phase-12-function-dmd